- Home
- BCAB vs CANF Comparison
BCAB vs CANF Comparison
Compare BCAB & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BCAB | CANF |
|---|---|---|
| Founded | 2007 | 1994 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 6.0M |
| IPO Year | 2020 | 2011 |
Fundamental Metrics
Financial Performance| Metric | BCAB | CANF |
|---|---|---|
| Price | $3.39 | $3.16 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 2 |
| Target Price | N/A | ★ $50.00 |
| AVG Volume (30 Days) | 44.0K | ★ 1.6M |
| Earning Date | 05-08-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.86 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $300,000.00 | N/A |
| Revenue This Year | N/A | $2,715,455.50 |
| Revenue Next Year | N/A | $101.06 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.12 | $0.17 |
| 52 Week High | $6.52 | $10.40 |
Technical Indicators
Market Signals| Indicator | BCAB | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 43.44 | 49.71 |
| Support Level | $3.31 | $3.18 |
| Resistance Level | $4.24 | $3.60 |
| Average True Range (ATR) | 0.30 | 0.17 |
| MACD | -0.07 | -0.02 |
| Stochastic Oscillator | 24.26 | 29.66 |
Price Performance
Historical ComparisonAbout BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.